Staff Members - Benha University
Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals
• 2022
Publication Information
Authors
1
Said E.M,
2Dalia.M.Nour El Din ,3Elawady.MA, 1
S.Y.Ragab, 1Tamer.E.Eleraky
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background and Aims: In Egypt, compulsory vaccination against hepatitis B
virus (HBV) infection started in 1992. Patients with chronic hepatitis C (CHC) should
be vaccinated against HBV. The aim was to assess the response to HBV vaccine in
CHC patients treated with direct acting antivirals (DDAs) in comparison to treatmentnaive patients and healthy subjects. Method: This retrospective-prospective study was
carried out on 360 consecutive adult subjects subdivided into 3 groups. Group I
included 150 CHC patients who vaccinated after getting sustained virologic response
(SVR) following treatment with DAAs. Group II comprised 110 CHC treatmentnaive patients while the control group comprised 100 healthy subjects. Three
intramuscular 20 µg doses (at 0, 1 & 6 months) of HBV-vaccine (rDNA) were
administered; HBs Ab titres were evaluated 6 – 8 weeks after the 3rd dose. Results:
CHC patients (treated or treatment-naïve) had highly significant lower mean HBs Ab
titre than controls. Twelve patients in group I (8%) had no response to HBV vaccine
in comparison to 4.5% in group II and 1% controls. About 83.3%in group I compared
to 85.5% in group II and 98% controls had a good response. In CHC treated patients,
HBsAb titre was negatively associated with FIB-4 score, fibrosis stage and ALT
levels while positively associated with platelet count. The fibrosis stage was the most
significant predictor of weak response. Conclusion: CHC Patients demonstrate a
significantly weak response to HBV vaccine. Concomitant DAAs treatment does not
influence response.
virus (HBV) infection started in 1992. Patients with chronic hepatitis C (CHC) should
be vaccinated against HBV. The aim was to assess the response to HBV vaccine in
CHC patients treated with direct acting antivirals (DDAs) in comparison to treatmentnaive patients and healthy subjects. Method: This retrospective-prospective study was
carried out on 360 consecutive adult subjects subdivided into 3 groups. Group I
included 150 CHC patients who vaccinated after getting sustained virologic response
(SVR) following treatment with DAAs. Group II comprised 110 CHC treatmentnaive patients while the control group comprised 100 healthy subjects. Three
intramuscular 20 µg doses (at 0, 1 & 6 months) of HBV-vaccine (rDNA) were
administered; HBs Ab titres were evaluated 6 – 8 weeks after the 3rd dose. Results:
CHC patients (treated or treatment-naïve) had highly significant lower mean HBs Ab
titre than controls. Twelve patients in group I (8%) had no response to HBV vaccine
in comparison to 4.5% in group II and 1% controls. About 83.3%in group I compared
to 85.5% in group II and 98% controls had a good response. In CHC treated patients,
HBsAb titre was negatively associated with FIB-4 score, fibrosis stage and ALT
levels while positively associated with platelet count. The fibrosis stage was the most
significant predictor of weak response. Conclusion: CHC Patients demonstrate a
significantly weak response to HBV vaccine. Concomitant DAAs treatment does not
influence response.